Indian Journal of Pharmacy Practice., 2026; 19(2):139-150.
https://www.ijopp.org

Review Article

EGFR Inhibitors: Current Status, Resistance Mechanisms, and Market Insight

Vidya Kishanrao Magar[1,*], Karna Bhagwanrao Khavane[2]

[1]Department of Pharmaceutical Chemistry, Srinath College of Pharmacy, Chhatrapati Sambhajinagar, Maharashtra, INDIA.
[2]Department of Pharmacology, Dr. Vedprakash Patil Pharmacy College, Chhatrapati Sambhajinagar, Maharashtra, INDIA.

ABSTRACT

The Epidermal Growth Factor Receptor (EGFR) is a pivotal oncogenic driver in Non-Small Cell Lung Cancer (NSCLC) and other epithelial malignancies. Over the past two decades, successive generations of EGFR Tyrosine Kinase Inhibitors (TKIs) have transformed the therapeutic landscape, beginning with reversible first-generation agents like gefitinib and erlotinib, progressing to irreversible second-generation TKIs such as afatinib, and culminating in third-generation agents like osimertinib, designed to overcome T790M-mediated resistance. However, despite initial efficacy, therapeutic resistance invariably emerges-most notably via the EGFR C797S mutation or through bypass mechanisms including MET amplification, HER2 activation, histologic transformation, and downstream pathway mutations (e.g., PIK3CA, KRAS). Fourth-generation EGFR inhibitors-comprising allosteric and non-covalent ATP-competitive agents-are now in early clinical evaluation to target triple-mutant EGFR (L858R/T790M/C797S) tumors. The EGFR-targeted therapy market, valued at USD 9-10 billion in 2023, is projected to exceed USD 15 billion by 2032, driven by drug innovation, expanded access to molecular diagnostics, and rising EGFR mutation prevalence, particularly in Asia-Pacific. Furthermore, novel therapeutic modalities such as bispecific antibodies (e.g., amivantamab), antibody-drug conjugates, and AI-driven resistance prediction models are redefining treatment personalization. This review provides a comprehensive analysis of the mechanistic evolution of EGFR inhibitors, resistance landscapes beyond C797S, emerging fourth-generation strategies, and market dynamics-highlighting future directions in precision oncology.

Keywords: EGFR inhibitors, Non-small cell lung cancer, Resistance mechanisms, C797S mutation, Targeted therapy, Fourth-generation TKIs, Market trends, Precision oncology.

Correspondence:
Dr. Vidya Kishanrao Magar
Department of Pharmaceutical Chemistry, Srinath College of Pharmacy, Chhatrapati Sambhajinagar-431136, Maharashtra, INDIA.
Email: vidyamagar87@gmail.com

Received: 09-07-2025;
Revised: 24-09-2025;
Accepted: 11-11-2025.

INTRODUCTION

The Epidermal Growth Factor Receptor (EGFR) is a pivotal component of cellular signaling networks that regulate proliferation, differentiation, and survival. As a member of the ErbB family of receptor tyrosine kinases, EGFR comprises an extracellular ligand-binding domain, a single transmembrane segment, and a cytoplasmic tyrosine kinase domain that becomes activated upon ligand-induced dimerization. This activation triggers downstream pathways, including RAS/RAF/MEK/ERK, PI3K/AKT/mTOR, and JAK/STAT, which control various aspects of cellular homeostasis and growth (Yarden & Sliwkowski, 2001; Normanno *et al*., 2006).

Aberrations in the EGFR pathway-such as gene amplification, protein overexpression, or activating mutations-are commonly implicated in the pathogenesis of several epithelial malignancies. These alterations disrupt the balance between growth-promoting and inhibitory signals, thereby promoting oncogenic transformation. EGFR abnormalities are frequently observed in Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), and Head and Neck Squamous Cell Carcinoma (HNSCC), among others (Sharma *et al*., 2007; Midha *et al*., 2015).

In NSCLC, EGFR mutations are particularly well-characterized. The two most prevalent activating mutations are exon 19 deletions and the L858R point mutation in exon 21, which collectively account for approximately 85-90% of EGFR-mutated cases. These genetic alterations enhance receptor tyrosine kinase activity and drive constitutive signaling, making the tumor cells highly dependent on EGFR for survival-a phenomenon termed "oncogene addiction" (Lynch *et al*., 2004; Mok *et al*., 2009). As a result, these tumors exhibit heightened sensitivity to targeted inhibition of EGFR.

The clinical significance of EGFR mutations in NSCLC has been transformative. With the advent of Tyrosine Kinase Inhibitors (TKIs), patients harboring sensitizing mutations can

DOI: 10.5530/ijopp.20260496

now be treated with molecularly tailored agents rather than conventional chemotherapy. This shift has markedly improved response rates, Progression-Free Survival (PFS), and quality of life in affected patients. For example, first-generation EGFR TKIs such as gefitinib and erlotinib initially showed remarkable efficacy in mutation-positive patients but were later replaced by third-generation agents like osimertinib, which are not only more potent but also active against resistant mutations such as T790M (Soria *et al*., 2018; Rosell *et al*., 2012; Thress *et al*., 2015).

Beyond lung cancer, EGFR overexpression has also been validated as a therapeutic target in colorectal and head and neck cancers. However, in these tumors, the effectiveness of monoclonal antibodies such as cetuximab and panitumumab is highly contingent upon the absence of downstream activating mutations in KRAS, NRAS, or BRAF, which can independently activate the same downstream pathways and negate EGFR blockade (Douillard *et al*., 2013; Bonner *et al*., 2006).

Taken together, EGFR represents one of the most thoroughly validated targets in oncology. Its aberrant activation contributes to both tumorigenesis and treatment resistance, underscoring its central role in cancer biology and its continuing relevance as a target for molecular therapies.

GENERATIONAL PROGRESSION OF EGFR TKIS

First-Generation Tkis

First-Generation EGFR Tyrosine Kinase Inhibitors

The development of first-generation EGFR Tyrosine Kinase Inhibitors (TKIs), such as gefitinib and erlotinib, marked a significant breakthrough in targeting abnormal EGFR signaling in cancer. These small-molecule drugs were specifically engineered to reversibly and competitively bind to the ATP-binding pocket of the EGFR tyrosine kinase domain. By occupying this site, they inhibit EGFR autophosphorylation and subsequently block the activation of downstream signaling cascades, including the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR pathways, which are essential for tumor cell proliferation and survival (Barker *et al*., 2001; Seshacharyulu *et al*., 2012).

Mechanism of Action

Gefitinib and erlotinib, both belonging to the quinazoline class of compounds, are structurally similar to ATP and function by competitively binding to the ATP pocket within the EGFR tyrosine kinase domain. This interaction effectively blocks autophosphorylation of key tyrosine residues on EGFR, thereby suppressing signaling pathways responsible for cell proliferation and survival. Notably, these inhibitors demonstrate higher potency against mutated forms of EGFR, such as the L858R point mutation and exon 19 deletions, compared to the wild-type receptor. This selective inhibition is a critical factor in their clinical efficacy in EGFR-mutated Non-Small Cell Lung Cancer (NSCLC) (Yun *et al*., 2008).

Clinical Development

Gefitinib (ZD1839) was the first EGFR Tyrosine Kinase Inhibitor (TKI) to be evaluated in clinical trials and received accelerated FDA approval in 2003 for advanced Non-Small Cell Lung Cancer (NSCLC), following encouraging outcomes in early-phase studies. Erlotinib (OSI-774) entered the clinical landscape soon after and demonstrated a significant survival benefit in the landmark BR.21 phase III trial, which included previously treated NSCLC patients (Shepherd *et al*., 2005). Initially, both agents were approved without consideration of EGFR mutation status.

A major turning point came with the identification of activating EGFR mutations-particularly exon 19 deletions and the L858R point mutation-as reliable predictive markers for response to EGFR TKIs. Subsequent randomized trials, including IPASS and WJTOG3405, confirmed the clinical advantage of gefitinib over standard platinum-based chemotherapy in patients with mutation-positive tumors. These findings established first-generation EGFR TKIs as the preferred first-line therapy for this genetically defined subset of NSCLC (Mok *et al*., 2009; Maemondo *et al*., 2010).

Efficacy

In patients with activating EGFR mutations, treatment with first-generation TKIs such as gefitinib and erlotinib has yielded Objective Response Rates (ORR) of approximately 60-80%. These agents have also extended Progression-Free Survival (PFS) to around 9 to 13 months, outcomes that significantly surpass those of conventional chemotherapy, which is associated with lower efficacy and greater toxicity (Rosell *et al*., 2009; Shepherd *et al*., 2005).

Limitations and Resistance

Despite these encouraging initial results, resistance to first-generation EGFR TKIs generally develops within 9 to 14 months of treatment onset. The most commonly identified resistance mechanism is the T790M mutation in exon 20 of the EGFR gene. This gatekeeper mutation enhances the receptor's affinity for ATP, thereby reducing the binding efficiency of gefitinib and erlotinib and limiting their therapeutic effects (Kobayashi *et al*., 2005). Additional resistance pathways have also been reported and contribute to disease progression in a subset of patients.

In addition to the T790M mutation, several other resistance mechanisms to first-generation EGFR TKIs have been identified. These include amplification of the MET proto-oncogene, which activates downstream signaling independent of EGFR; overexpression of HER2, contributing to bypass signaling; and histological transformation of the tumor, such as conversion

from adenocarcinoma to small cell lung cancer. Furthermore, secondary mutations in other oncogenic drivers, including PIK3CA and BRAF, can also lead to therapeutic resistance (Sequist *et al*., 2011). These resistance mechanisms ultimately paved the way for the development of second- and third-generation TKIs with enhanced efficacy and ability to overcome T790M-mediated resistance.

SECOND-GENERATION EGFR TYROSINE KINASE INHIBITORS

Second-generation EGFR Tyrosine Kinase Inhibitors (TKIs) were engineered to overcome resistance mechanisms that frequently develop during treatment with first-generation inhibitors, especially the T790M gatekeeper mutation. Unlike their reversible predecessors, agents such as afatinib and dacomitinib form a covalent bond with the Cysteine residue at position 797 (Cys797) in the EGFR kinase domain, resulting in irreversible inhibition. These compounds also inhibit multiple members of the ErbB receptor family, including HER2 (ErbB2) and HER4 (ErbB4), thus exerting a more comprehensive blockade of oncogenic signaling across related pathways (Solca *et al*., 2012; Smaill *et al*., 2016).

Mechanism of Action

Second-generation EGFR inhibitors utilize an electrophilic Michael acceptor group that forms a covalent bond with the Cysteine residue at position 797 (Cys797) within the ATP-binding pocket of EGFR. This covalent interaction leads to irreversible inhibition of EGFR autophosphorylation, resulting in sustained suppression of critical oncogenic pathways, including PI3K/AKT and RAS/RAF/MEK/ERK. Additionally, their ability to inhibit other ErbB receptors, such as HER2 and HER3, may help mitigate compensatory signaling—a known mechanism of resistance to EGFR-targeted monotherapy (Engelman *et al*., 2007).

Afatinib (BIBW 2992) and dacomitinib (PF-00299804) were designed to potently inhibit common EGFR-activating mutations like exon 19 deletions and L858R. They also demonstrated some activity against the T790M resistance mutation in preclinical models (Li *et al*., 2008). However, their clinical efficacy in T790M-positive tumors was limited, primarily due to toxicity caused by inhibition of wild-type EGFR, which restricted dose escalation (Walter *et al*., 2013).

Clinical Efficacy

Afatinib received regulatory approval in 2013 following results from the LUX-Lung 3 and LUX-Lung 6 phase III trials, which demonstrated its clinical advantage over platinum-based doublet chemotherapy in treatment-naïve patients with EGFR-mutated Non-Small Cell Lung Cancer (NSCLC). Subgroup analyses from both studies indicated that afatinib was especially effective in individuals with exon 19 deletions, achieving Progression-Free Survival (PFS) durations between 11.0 and 13.6 months and Objective Response Rates (ORR) exceeding 60% (Sequist *et al*., 2013; Wu *et al*., 2014).

Dacomitinib, another second-generation EGFR TKI, was assessed in the ARCHER 1050 phase III clinical trial. This study demonstrated that dacomitinib significantly improved both median Overall Survival (OS) and PFS compared to gefitinib in patients with sensitizing EGFR mutations. The median OS was extended to 34.1 months with dacomitinib, in contrast to 26.8 months with gefitinib (hazard ratio [HR] = 0.76, p = 0.0438) (Mok *et al*., 2017).

Adverse Events

The broader inhibitory activity of second-generation EGFR Tyrosine Kinase Inhibitors (TKIs) has been associated with a higher incidence and severity of adverse events. Frequently reported toxicities include grade 3 or higher diarrhea, oral mucositis, acneiform rash, and paronychia. These side effects often require dose reductions, temporary treatment interruptions, or even discontinuation, potentially affecting the long-term therapeutic efficacy and overall quality of life for patients undergoing treatment (Planchard & Besse, 2019).

Limitations

Although second-generation EGFR Tyrosine Kinase Inhibitors (TKIs) offer broader and more potent inhibition than their predecessors, they are generally ineffective against T790M-positive tumor clones in vivo. The T790M mutation increases the affinity of EGFR for ATP, which diminishes the ability of these inhibitors to effectively bind and suppress kinase activity (Cross *et al*., 2014). Additionally, the increased toxicity associated with pan-ErbB inhibition limits the feasibility of dose intensification. These limitations prompted the development of third-generation TKIs, which are structurally designed to selectively target mutant EGFR—including T790M—while sparing wild-type receptors. This approach significantly reduces off-target toxicities and improves therapeutic outcomes (Yu *et al*., 2013).

THIRD-GENERATION EGFR TYROSINE KINASE INHIBITORS

The T790M mutation in exon 20 of the EGFR gene is the most frequently observed mechanism of acquired resistance to first- and second-generation EGFR Tyrosine Kinase Inhibitors (TKIs), contributing to approximately 50-60% of therapeutic failures in EGFR-mutant Non-Small Cell Lung Cancer (NSCLC) (Cross *et al*., 2014). This mutation alters the kinase domain by increasing its affinity for ATP, which limits the binding and inhibitory activity of both reversible and irreversible earlier-generation TKIs. In response to this resistance mechanism, third-generation EGFR inhibitors such as osimertinib, nazartinib, and olmutinib were developed. These agents are designed to selectively inhibit both

common EGFR-activating mutations and the T790M resistance mutation, while sparing wild-type EGFR. This selectivity helps to enhance therapeutic efficacy while minimizing adverse effects (Jänne *et al*., 2015; Thress *et al*., 2015).

Mechanism of Action

Third-generation EGFR Tyrosine Kinase Inhibitors (TKIs) are structurally optimized to function as irreversible, mutant-selective inhibitors that covalently bind to the Cysteine 797 (Cys797) residue in the EGFR kinase domain. In contrast to second-generation agents, they demonstrate preferential binding to mutant EGFR variants—such as L858R, exon 19 deletions, and T790M—while sparing wild-type EGFR. This molecular selectivity significantly reduces off-target toxicity and improves treatment outcomes in resistant tumors (Finlay *et al*., 2014).

Osimertinib (AZD9291) is the most clinically validated agent in this class and exhibits robust inhibitory activity against both sensitizing and T790M-mediated resistance mutations, with limited activity against wild-type EGFR (Ballard *et al*., 2015). Preclinical models revealed that osimertinib is over 200 times more selective for EGFR T790M than for wild-type EGFR, offering a substantial advantage over prior generations of EGFR inhibitors (Mok *et al*., 2017).

Clinical Development and Efficacy

In 2015, osimertinib received accelerated approval from the U.S. Food and Drug Administration (FDA) for the treatment of Non-Small Cell Lung Cancer (NSCLC) patients harboring the EGFR T790M resistance mutation. This approval was based on results from the AURA clinical trials, which reported an objective response rate of approximately 60% and a median Progression-Free Survival (PFS) of 9.6 months among patients who had progressed on prior EGFR TKI therapy (Reungwetwattana *et al*., 2018).

Osimertinib was later evaluated as a first-line treatment in the landmark FLAURA trial, which enrolled patients with newly diagnosed EGFR-mutated advanced NSCLC. Compared to first-generation EGFR TKIs such as gefitinib or erlotinib, osimertinib demonstrated significantly improved outcomes. Median PFS was 18.9 months with osimertinib versus 10.2 months with standard therapy (hazard ratio [HR] = 0.46; $p < .001$), while Overall Survival (OS) reached 38.6 months versus 31.8 months (HR = 0.80) (Soria *et al*., 2018). These results led to osimertinib becoming the preferred first-line therapy for EGFR-mutated NSCLC globally.

Safety Profile

Due to its structural design that selectively targets mutant forms of EGFR, osimertinib is generally associated with a more favorable safety profile compared to earlier-generation Tyrosine Kinase Inhibitors (TKIs). Frequently reported adverse effects include diarrhea, skin rash, nail abnormalities, and fatigue. Importantly, the incidence of severe gastrointestinal or dermatologic toxicities is lower with osimertinib than with second-generation agents such as afatinib and dacomitinib (Schoenfeld & Yu, 2020).

Resistance to Third-Generation TKIs

Although osimertinib has significantly advanced the treatment of EGFR-mutated Non-Small Cell Lung Cancer (NSCLC), its clinical effectiveness is often undermined by the eventual development of drug resistance. A prominent mechanism involves the emergence of the EGFR C797S mutation, which alters the cysteine residue at position 797—critical for covalent bonding with osimertinib—thereby abolishing its inhibitory activity (Thress *et al*., 2015). This mutation is particularly problematic in patients who initially responded to osimertinib due to T790M-mediated resistance.

Other common resistance mechanisms include amplification of the MET gene, which activates downstream signaling independently of EGFR, effectively bypassing the drug's inhibitory effects. Similarly, HER2 amplification serves as an alternative route for signal propagation, contributing to sustained tumor growth despite EGFR blockade.

In some cases, tumors undergo histological transformation, most notably converting from adenocarcinoma to small cell lung cancer, a phenotype typically unresponsive to EGFR TKIs. Additionally, resistance can be mediated by the activation of alternative oncogenic pathways, including mutations in KRAS and PIK3CA, both of which can independently drive cell survival and proliferation.

To address these complex and heterogeneous resistance profiles, research is now focused on the development of fourth-generation EGFR inhibitors capable of overcoming C797S and other resistant clones. Furthermore, combination therapy strategies-such as pairing osimertinib with MET inhibitors, PI3K inhibitors, or chemotherapy-are being actively explored in both clinical trials and preclinical models to prevent or delay the emergence of resistance.

To combat these mechanisms, fourth-generation EGFR inhibitors and combination therapy strategies are currently under investigation in clinical and preclinical settings.

FOURTH-GENERATION EGFR INHIBITORS

Although third-generation EGFR Tyrosine Kinase Inhibitors (TKIs) like osimertinib have significantly improved outcomes in patients with EGFR-mutated Non-Small Cell Lung Cancer (NSCLC), the emergence of acquired resistance-particularly due to the C797S mutation—poses a major therapeutic challenge. The C797S mutation results in the substitution of the cysteine residue at position 797 within the EGFR kinase domain, a site crucial for covalent bond formation with osimertinib. This alteration disrupts the drug's mechanism of action, rendering it ineffective.

Importantly, the C797S mutation can occur either in cis or in trans configuration with the T790M mutation. In the cis configuration (on the same allele), most available TKIs fail to exert any inhibitory activity. In the trans configuration (on different alleles), sequential combination strategies using first- and third-generation TKIs may retain some efficacy, though clinical outcomes remain limited. The summary of approved EGFR inhibitors, including their generations, mechanisms, and clinical indications, is depicted in Table 1.

To address these resistance mechanisms, a new class of fourth-generation EGFR inhibitors has been designed. These agents aim to selectively target C797S-mutated EGFR while retaining potent activity against common activating mutations such as exon 19 deletions and L858R, as well as the T790M resistance mutation. Unlike earlier TKIs, several of these investigational compounds operate through allosteric inhibition, binding to regions outside the ATP-binding site to modulate EGFR activity without relying on covalent interaction with C797 (Jia *et al*., 2016). This approach offers a promising strategy to circumvent resistance and extend the durability of EGFR-targeted therapies in advanced NSCLC. The common resistance mechanisms to EGFR TKIs and their associated therapeutic strategies are depicted in Table 2.

Structural and Mechanistic Advancements

Fourth-generation EGFR inhibitors have been structurally optimized to address resistance mechanisms particularly the C797S mutation by bypassing covalent interaction with the cysteine residue at position 797 in the kinase domain. Unlike earlier TKIs, these agents are designed to act through non-covalent mechanisms, including mutant-selective ATP-competitive binding or allosteric modulation. By targeting alternate conformations or distal binding pockets within EGFR, they retain activity against tumors harboring C797S mutations, either as a standalone alteration or in combination with other resistance mutations such as T790M (To *et al*., 2022; Fassunke *et al*., 2023).

A particularly promising subset of these next-generation drugs includes allosteric inhibitors, which interact with regions of the receptor that are spatially distinct from the ATP-binding site. Because they do not compete directly with ATP, these agents are less affected by structural alterations in the ATP pocket making them effective in tumors that are resistant to both first- and third-generation TKIs (Piotrowska *et al*., 2023). This alternative mechanism opens new therapeutic possibilities for patients with EGFR triple mutations, including those with L858R/T790M/C797S profiles.

NOTABLE COMPOUNDS UNDER DEVELOPMENT

Several fourth-generation EGFR inhibitors have demonstrated encouraging activity in preclinical and early clinical studies, particularly against tumors harboring complex resistance mutations such as EGFR C797S, T790M, and activating mutations like L858R and exon 19 deletions.

EAI045

EAI045 is among the earliest identified allosteric inhibitors specifically designed to target EGFR L858R/T790M/C797S triple-mutant alleles. Unlike ATP-competitive TKIs, EAI045 binds to a distinct allosteric pocket in the kinase domain, offering a non-covalent and non-ATP-competitive mechanism of action. However, it lacks sufficient activity as a monotherapy due to its inability to effectively inhibit EGFR homodimerization, necessitating co-administration with anti-EGFR monoclonal antibodies such as cetuximab to achieve meaningful antitumor effects. This combination has shown synergistic efficacy in preclinical models, serving as a proof-of-concept for allosteric inhibition in EGFR-mutant cancers (Suda *et al*., 2017).

JBJ-04-125-02

JBJ-04-125-02 is a structurally optimized derivative of EAI045 that demonstrates improved potency and monotherapy activity against EGFR-driven cancers. This compound exhibits stronger binding affinity and retains activity against multiple resistance mutations, including C797S. Additionally, when combined with anti-EGFR antibodies, JBJ-04-125-02 has shown robust tumor regression in animal models, indicating its potential as a dual-approach strategy. Although still in preclinical development, it represents an important advance in overcoming resistance to third-generation TKIs (Le *et al*., 2023).

BLU-945

BLU-945 is a mutant-selective fourth-generation EGFR inhibitor currently under evaluation in phase I clinical trials. It is engineered to inhibit a broad range of EGFR alterations—including activating mutations, T790M, and C797S—even when these coexist within cis configurations. Notably, BLU-945 avoids binding to wild-type EGFR, thus reducing off-target toxicity. Early trial data suggest favorable pharmacokinetic properties, good tolerability, and encouraging efficacy in patients previously treated with osimertinib, positioning BLU-945 as one of the most promising next-generation agents (Piotrowska *et al*., 2018).

BOS172738 and CH7233163

These investigational compounds are part of a newer wave of ATP-competitive inhibitors designed with structural flexibility and mutant selectivity. Both agents show activity against EGFR triple mutations, including C797S in both cis and trans configurations with T790M. Their unique scaffold modifications

enhance binding affinity to mutant forms of EGFR while minimizing interaction with wild-type receptors. While still in early-phase studies, they represent important additions to the therapeutic landscape aimed at overcoming multidrug resistance in EGFR-mutated NSCLC (Engelman *et al*., 2007).

CLINICAL OUTLOOK AND CHALLENGES

While fourth-generation EGFR inhibitors have demonstrated promising efficacy in preclinical models, their clinical translation is still in its nascent stages. One of the principal challenges in this context is tumor heterogeneity, where multiple resistance mechanisms can co-exist within the same tumor microenvironment. These may include alterations such as MET amplification, histologic transformation, or the emergence of alternative bypass signaling pathways. To address this complexity, combination therapeutic strategies are currently being explored. Notably, regimens that pair EGFR TKIs with MET inhibitors or immune checkpoint inhibitors are under investigation to delay or overcome acquired resistance (Sequist *et al*., 2020).

Another critical determinant of clinical success is achieving an optimal therapeutic window—one that enables selective inhibition of mutant EGFR while minimizing toxicity from wild-type EGFR blockade. Enhancing mutant specificity and refining dose optimization strategies will be essential to maximize efficacy and reduce adverse effects in future treatment paradigms.

RESISTANCE PATHWAYS BEYOND C797S

While the C797S mutation in exon 20 of the EGFR gene is a well-established mechanism of resistance to third-generation Tyrosine Kinase Inhibitors (TKIs), especially osimertinib, an array of alternative resistance pathways has also been identified. These mechanisms often occur independently of EGFR, revealing the intricate molecular heterogeneity and adaptive plasticity of Non-Small Cell Lung Cancer (NSCLC). Such complexity highlights the limitations of EGFR-targeted monotherapy and emphasizes the urgent need for integrated, multi-targeted treatment approaches to achieve durable responses (Li *et al*., 2018).

MET Amplification

MET proto-oncogene amplification represents one of the most common bypass mechanisms of acquired resistance following treatment with osimertinib, observed in approximately 15-20% of patients with EGFR-mutant NSCLC. This amplification activates the MET receptor tyrosine kinase, which subsequently triggers downstream signaling pathways such as PI3K/AKT and RAS/MAPK, thereby bypassing EGFR dependency (Garrison *et al*., 2023). Both preclinical models and early clinical data suggest that co-targeting EGFR and MET may restore therapeutic sensitivity in MET-amplified tumors. Ongoing investigations are evaluating the efficacy of MET inhibitors such as savolitinib, capmatinib, and tepotinib in combination with osimertinib in this context (Offin *et al*., 2019).

HER2 Amplification and Activation

Amplification or overexpression of HER2 (ErbB2) constitutes another significant mechanism through which tumor cells can bypass EGFR inhibition. HER2 activation promotes the formation of heterodimers with other ErbB family members, enabling ligand-independent signaling that sustains oncogenic pathways despite EGFR blockade. Preclinical studies have shown that HER2 amplification can co-occur with EGFR mutations and re-engage key downstream signaling cascades, such as the PI3K/AKT and MAPK pathways, leading to therapeutic resistance (Marcoux *et al*., 2019). In response, anti-HER2 therapeutic strategies—such as trastuzumab, trastuzumab deruxtecan, and the pan-ErbB inhibitor afatinib—are being actively investigated for their potential to overcome resistance in HER2-amplified or overexpressing NSCLC tumors (Garrison *et al*., 2023).

Histological Transformation

Tumors with activating EGFR mutations can develop resistance through histologic transformation, most notably into Small Cell Lung Cancer (SCLC) and, less commonly, squamous cell carcinoma. This phenotypic switch results in a loss of EGFR dependency and is frequently driven by concurrent inactivation of TP53 and RB1, genetic alterations that are characteristic of SCLC (Schoenfeld *et al*., 2020). Confirmation of transformation typically requires a repeat tissue biopsy. Once confirmed, the treatment approach shifts from EGFR-targeted therapy to cytotoxic chemotherapy, often employing regimens such as etoposide plus platinum-based agents, which are standard for SCLC management (Marcoux *et al*., 2019).

Activation of Downstream Signaling Pathways

Several resistance mechanisms emerge through mutations in downstream effectors of the EGFR signaling pathway, effectively bypassing receptor-level inhibition. For instance, PIK3CA mutations lead to constitutive activation of the PI3K/AKT/mTOR signaling cascade, diminishing the impact of upstream EGFR inhibition. Similarly, activating BRAF V600E mutations trigger the MAPK/ERK pathway independently of EGFR, contributing to therapeutic failure. Although KRAS G12C mutations have historically been considered mutually exclusive with EGFR mutations, emerging data suggest they can arise as secondary resistance mutations after EGFR TKI therapy, particularly in tumors exhibiting high intratumoral heterogeneity (Yu *et al*., 2020). To counter these alterations, targeted therapies such as alpelisib (a PI3K inhibitor), encorafenib (a BRAF inhibitor), and sotorasib (a KRAS G12C inhibitor) are currently being explored in combination regimens to improve outcomes in resistant disease states (Research And Markets, 2024).

MARKET DYNAMICS

FGFR, AXL, and IGF1R Activation

Beyond canonical resistance mechanisms, activation of alternative signaling pathways such as AXL, FGFR, and IGF1R has been implicated in acquired resistance to osimertinib. These pathways contribute to therapeutic failure through various bypass and compensatory mechanisms:

AXL overexpression is associated with Epithelial-to-Mesenchymal Transition (EMT), a phenotypic shift that enhances tumor cell plasticity, invasiveness, and survival signaling, reducing dependence on EGFR-mediated pathways.

FGFR1 amplification, often seen in mesenchymal-like NSCLC subtypes, can sustain proliferative signaling independent of EGFR, particularly under selective pressure from TKIs.

IGF1R upregulation activates the PI3K/AKT axis through an alternative route, thereby maintaining oncogenic signaling despite EGFR inhibition (AstraZeneca, 2023).

To counteract these mechanisms, targeted inhibitors such as bemcentinib (AXL inhibitor), erdafitinib (FGFR inhibitor), and linsitinib (IGF1R inhibitor) are under evaluation in preclinical models and early-phase clinical trials. These approaches offer a potential path toward overcoming resistance heterogeneity and improving the durability of EGFR-targeted therapy.

MARKET VALUE

Global Market Trends

The global market for Epidermal Growth Factor Receptor (EGFR) inhibitors was valued at an estimated USD 8-10 billion in 2023 and is projected to grow to USD 15-17 billion by 2030-2032, reflecting a Compound Annual Growth Rate (CAGR) of approximately 7-10%. This growth is fueled by several key factors, including the rising global incidence of Non-Small Cell Lung Cancer (NSCLC), wider implementation of molecular diagnostics, and the continued launch of next-generation EGFR-targeted therapies across both high-income and developing regions (Checkpoint Therapeutics, 2024; J&J Pharmaceuticals, 2023).

Leading Companies and Products

A number of pharmaceutical companies are spearheading innovation in the EGFR inhibitor space:

AstraZeneca remains a market leader with osimertinib (Tagrisso), a third-generation EGFR TKI that has become the standard of care for first-line treatment in patients with EGFR-mutated NSCLC.

Boehringer Ingelheim markets afatinib, an irreversible pan-ErbB family blocker, indicated for patients with common and some uncommon EGFR mutations.

Table 1: Summary of Approved EGFR Inhibitors.

Drug Name	Generation	Mechanism of Action	Approval Year	Clinical Indications	Notable Features
Gefitinib	First	Reversible ATP-competitive inhibitor	2003 (re-approved 2015)	EGFR-mutant NSCLC (exon 19 del, L858R)	First approved EGFR TKI
Erlotinib	First	Reversible ATP-competitive inhibitor	2004	Advanced NSCLC with EGFR mutations; pancreatic cancer	Also used in pancreatic cancer
Afatinib	Second	Irreversible ErbB1/2/4 blocker	2013	NSCLC with uncommon EGFR mutations	Broader ErbB family inhibition
Dacomitinib	Second	Irreversible pan-HER inhibitor	2018	First-line EGFR-mutant NSCLC	Improved PFS vs. gefitinib
Osimertinib	Third	Irreversible inhibitor (T790M-selective)	2015 (T790M), 2018 (1st-line)	EGFR T790M+ NSCLC; First-line EGFR-mutant NSCLC	CNS penetration; widely adopted
Amivantamab	n/a (antibody)	EGFR/MET bispecific antibody	2021	EGFR exon 20 insertion mutations in NSCLC	First-in-class bispecific antibody
Lazertinib	Third	Irreversible EGFR TKI, T790M active	2021 (South Korea)	T790M-positive NSCLC	Being combined with amivantamab

Sources: AstraZeneca (2023), Checkpoint Therapeutics (2024), J&J Pharmaceuticals (2023); FDA and EMA product labels; company press releases.

Table 2: Common Resistance Mechanisms to EGFR TKIs and Associated Therapeutic Strategies.

Resistance Mechanism	Associated Mutation/ Pathway	Frequency	Impacted Drugs	Emerging Solutions
T790M mutation	EGFR exon 20	~50-60% (post 1st/2nd gen TKIs)	Gefitinib, erlotinib, afatinib	Osimertinib (3rd-generation TKI)
C797S mutation	EGFR exon 20	~20-30% (post osimertinib)	Osimertinib, lazertinib	4th-gen TKIs (e.g., JBJ-04-125-02, BLU-945)
MET amplification	MET gene	15-20%	All EGFR TKIs	MET inhibitors (e.g., savolitinib)
HER2 amplification	ERBB2 gene	5-10%	Osimertinib, afatinib	Trastuzumab deruxtecan, afatinib
Histologic transformation	Adenocarcinoma → SCLC	~5-10%	All TKIs	Chemotherapy (etoposide + platinum)
PIK3CA mutation	PI3K/AKT/mTOR pathway	~5%	All TKIs	PI3K inhibitors (e.g., alpelisib)
BRAF V600E mutation	MAPK pathway	Rare	All TKIs	BRAF inhibitors (e.g., encorafenib + cetuximab)
AXL activation	EMT and bypass signaling	Variable	All TKIs	AXL inhibitors (e.g., bemcentinib)
KRAS mutation (G12C)	MAPK/ERK pathway	Rare in EGFR+ NSCLC	All TKIs	KRAS G12C inhibitors (e.g., sotorasib)

Note: Frequency estimates are based on post-treatment resistance patterns in EGFR-mutant NSCLC. Data were derived from pivotal clinical trials (AURA, FLAURA) and recent literature reviews and studies (Li *et al.*, 2018; Marcoux *et al.*, 2019; Thress *et al.*, 2015; Sequist *et al.*, 2020).

Johnson & Johnson, via its subsidiary Janssen, has developed amivantamab, a bispecific monoclonal antibody targeting both EGFR and MET, which has gained FDA approval for use in EGFR exon 20 insertion-mutant NSCLC.

Checkpoint Therapeutics is advancing olafertinib (CK-101), a third-generation EGFR TKI, currently in Phase III clinical trials for treatment-naïve patients with EGFR-mutated NSCLC (Zhou *et al.*, 2011; Goto *et al.*, 2023; Melosky *et al.*, 2015).

Regional Growth Dynamics

The Asia-Pacific region, particularly China, is anticipated to experience the highest growth rate in the EGFR inhibitor market. This trajectory is primarily driven by the elevated prevalence of EGFR mutations, which may be present in up to 40% of NSCLC cases within certain Asian populations. The region is also benefitting from the rapid expansion of molecular diagnostics infrastructure, increased availability of targeted therapies, and favorable national reimbursement policies in countries like China and South Korea. These combined factors are significantly enhancing patient access and driving market expansion (Fassunke *et al.*, 2023).

Antibody-Drug Conjugates and Supportive Care Markets

The Asia-Pacific region, particularly China, is anticipated to experience the highest growth rate in the EGFR inhibitor market. This trajectory is primarily driven by the elevated prevalence of EGFR mutations, which may be present in up to 40% of NSCLC cases within certain Asian populations. The region is also benefitting from the rapid expansion of molecular diagnostics infrastructure, increased availability of targeted therapies, and favorable national reimbursement policies in countries like China and South Korea. These combined factors are significantly enhancing patient access and driving market expansion (Fassunke *et al.*, 2023).

Antibody-Drug Conjugates and Supportive Care Markets

Emerging therapeutic platforms, particularly Antibody-Drug Conjugates (ADCs), are reshaping the treatment landscape for EGFR-mutant NSCLC. Agents such as datopotamab deruxtecan have shown promising activity in patients who have progressed on osimertinib, representing a new treatment avenue for EGFR-TKI-resistant disease (Le *et al.*, 2023).

Parallel to therapeutic innovations, the supportive care market targeting EGFR inhibitor-induced dermatologic toxicities is also expanding. Acneiform rash, a common adverse event, affects up to 90% of patients treated with EGFR TKIs, often necessitating dose modifications or discontinuation. This side effect has created a niche but rapidly growing market, with a projected CAGR of approximately 18% through 2035, driven by the development of specialized dermatologic agents, personalized skincare regimens, and preventive dermatologic care protocols (Sequist *et al.*, 2020).

FUTURE PERSPECTIVES

The landscape of EGFR-targeted therapy in Non-Small Cell Lung Cancer (NSCLC) continues to evolve rapidly, shaped by deeper molecular understanding, resistance mechanisms, and therapeutic innovation. While significant strides have been made with the introduction of first-, second-, and third-generation EGFR Tyrosine Kinase Inhibitors (TKIs), as well as fourth-generation compounds currently in development, drug resistance remains an inevitable challenge, particularly in the form of C797S mutation, MET amplification, and histologic transformation.

Overcoming Resistance through Combinatorial Approaches

Future therapeutic strategies will likely emphasize combination regimens designed to simultaneously target EGFR mutations and co-occurring or bypass resistance pathways. Promising avenues include:

- EGFR TKI + MET inhibitors (e.g., osimertinib + savolitinib).
- EGFR TKI + anti-HER3 or HER2 therapies.
- Dual TKI blockade or TKI + ADC combinations.

These approaches aim to delay resistance onset and provide tailored options based on molecular resistance profiles, as determined by liquid biopsy and Next-Generation Sequencing (NGS).

Role of Immunotherapy and Tumor Microenvironment Modulation

Historically, immune checkpoint inhibitors have shown limited efficacy in EGFR-mutant NSCLC due to a non-inflamed tumor microenvironment. However, rational combinations of EGFR TKIs with immune modulators, such as anti-PD-1/PD-L1 antibodies, STING agonists, or VEGF inhibitors, are under early-phase investigation. Additionally, therapies that modulate the Tumor Microenvironment (TME) to improve immune infiltration may offer new possibilities for durable responses.

Next-Generation EGFR Inhibitors and ADCs

The emergence of allosteric, non-covalent EGFR inhibitors capable of overcoming C797S resistance—such as BLU-945, JBJ-04-125-02, and EAI045 derivatives—marks a paradigm shift in drug design. These agents provide mutant-selective inhibition while sparing wild-type EGFR, minimizing toxicity. Similarly, Antibody-Drug Conjugates (ADCs) like datopotamab deruxtecan offer promise in TKI-resistant settings by directly delivering cytotoxic payloads to EGFR-expressing tumor cells, including those with resistance mutations.

Personalized Medicine and Molecular Monitoring

The future of EGFR-targeted therapy will increasingly rely on precision medicine frameworks:

- Real-time circulating tumor DNA (ctDNA) monitoring to detect emerging resistance mutations.
- Dynamic treatment switching based on evolving molecular profiles.
- Predictive biomarkers to guide initial therapy selection and avoid unnecessary toxicity.

This individualized approach holds the potential to extend progression-free and overall survival while preserving quality of life.

Market and Accessibility Outlook

From a translational and commercial perspective, expanding access to molecular diagnostics and reimbursement for targeted therapies in resource-limited regions will be crucial. The rising incidence of EGFR-mutant NSCLC in Asia and increased investment in regional clinical trials highlight the importance of inclusive, global drug development strategies.

CONCLUSION

The therapeutic landscape of EGFR-mutant NSCLC has evolved considerably—from first-generation reversible TKIs to third-generation inhibitors like osimertinib, which overcome T790M resistance. However, tertiary resistance mutations such as C797S and multiple bypass pathways now limit the durability of responses. Emerging fourth-generation inhibitors, designed to target C797S via non-covalent or allosteric mechanisms, are undergoing clinical validation. Meanwhile, combination regimens, AI-driven predictive tools, and next-generation ADCs are collectively shaping a multi-modal strategy to extend survival and improve outcomes. Coupled with a growing global market—projected to exceed USD 15 billion by 2032—EGFR-targeted therapy remains a cornerstone of precision oncology, with continued innovation expected to drive the next wave of breakthroughs.

ACKNOWLEDGEMENT

The authors sincerely thank Dr. Santosh Shelke, Principal of Srinath College of Pharmacy, for his continuous encouragement, valuable guidance, and institutional support throughout the course of this work. The authors also express their gratitude to the Management of Srinath College of Pharmacy for providing the necessary facilities and a conducive research environment that enabled the successful completion of this study.

ABBREVIATIONS

EGFR: Epidermal Growth Factor Receptor; **NSCLC:** Non-Small Cell Lung Cancer; **TKI:** Tyrosine Kinase Inhibitor; **ORR:** Objective Response Rate; **PFS:** Progression-Free Survival; **OS:** Overall Survival; **SCLC:** Small Cell Lung Cancer; **ADC:** Antibody-Drug Conjugate; **FDA:** Food and Drug Administration; **HER2:** Human Epidermal Growth Factor Receptor 2 (ErbB2); **HER3:** Human Epidermal Growth Factor Receptor 3 (ErbB3); **MET:** Mesenchymal-Epithelial Transition Factor; **PI3K:** Phosphoinositide 3-Kinase; **AKT:** Protein Kinase B; **mTOR:** Mammalian Target of Rapamycin; **MAPK:** Mitogen-Activated Protein Kinase; **EMT:** Epithelial-Mesenchymal Transition; **ctDNA:** Circulating Tumor DNA; **NGS:** Next-Generation Sequencing; **PD-1:** Programmed Cell Death Protein 1; **PD-L1:** Programmed Death-Ligand 1; **IGF1R:** Insulin-Like Growth Factor 1 Receptor; **FGFR:** Fibroblast Growth Factor Receptor; **AXL:** AXL Receptor Tyrosine Kinase; **KRAS:** Kirsten Rat Sarcoma Viral Oncogene Homolog; **BRAF:** v-Raf Murine Sarcoma Viral Oncogene Homolog B; **BLU-945:** A Fourth-Generation EGFR Inhibitor; **JBJ-04-125-02:** Allosteric EGFR Inhibitor; **EAI045:** Experimental Allosteric EGFR Inhibitor.

CONFLICT OF INTEREST

The authors declare that they have no conflict of interest.

SUMMARY

This review article comprehensively explores Epidermal Growth Factor Receptor (EGFR) as a pivotal target in the treatment of Non-Small Cell Lung Cancer (NSCLC). First-generation EGFR Tyrosine Kinase Inhibitors (TKIs) like gefitinib and erlotinib revolutionized treatment for patients with sensitizing EGFR mutations, demonstrating superior response rates and progression-free survival compared to chemotherapy. However, acquired resistance—primarily due to the T790M mutation—prompted the development of second-generation inhibitors (e.g., afatinib, dacomitinib), which irreversibly bind EGFR but were limited by toxicity and poor efficacy against T790M.

Third-generation TKIs, especially osimertinib, offered a breakthrough by selectively targeting both activating mutations and T790M, while sparing wild-type EGFR. Osimertinib became the standard first-line therapy due to its impressive efficacy and safety profile. Despite this advancement, resistance to osimertinib eventually emerges through diverse mechanisms such as C797S mutation, MET/HER2 amplification, histologic transformation, and activation of bypass pathways (e.g., PIK3CA, KRAS, BRAF mutations).

To address these challenges, fourth-generation inhibitors (e.g., BLU-945, JBJ-04-125-02) are under development. These compounds are designed to overcome C797S-mediated resistance through non-covalent and allosteric mechanisms. In parallel, combination strategies involving MET inhibitors, Antibody-Drug Conjugates (ADCs), and immune checkpoint inhibitors are under clinical evaluation.

The review also highlights the commercial landscape, noting a robust market expansion driven by improved diagnostics, growing mutation prevalence (especially in Asia), and next-generation drug approvals. Emerging areas include personalized therapy, liquid biopsy monitoring, and management of EGFR inhibitor-induced toxicities, which together are shaping the future of precision oncology in EGFR-mutated NSCLC.

REFERENCES

AstraZeneca. (2023). Tagrisso (osimertinib) product information. Retrieved from https://www.astrazeneca.com

Ballard, P., Yates, J. W., Yang, Z., Kim, D. W., Yang, J. C., Cantarini, M., *et al.* (2015). Preclinical comparison of osimertinib with other EGFR inhibitors in EGFR-mutant NSCLC models. Cancer Research, 75(15 Supplement), Abstract 2368. https://doi.org/10.1158/1538-7445.AM2015-2368

Barker, A. J., Gibson, K. H., Grundy, W., Godfrey, A. A., Barlow, J. J., Healy, M. P., *et al.* (2001). Studies leading to the identification of ZD1839 (Iressa): An orally active, selective EGFR tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorganic & Medicinal Chemistry Letters, 11(14), 1911-1914. https://doi.org/10.1016/S0960-894X(01)00320-5

Bonner, J. A., Harari, P. M., Giralt, J., Azarnia, N., Shin, D. M., Cohen, R. B., *et al.* (2006). Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. The New England Journal of Medicine, 354(6), 567-578. https://doi.org/10.1056/NEJMoa053422

Checkpoint Therapeutics. (2024). Clinical development pipeline: Olafertinib (CK-101). Retrieved from https://www.checkpointtx.com

Cross, D. A., Ashton, S. E., Ghiorghiu, S., Eberlein, C., Nebhan, C. A., Spitzler, P. J., *et al.* (2014). AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discovery, 4(9), 1046-1061. https://doi.org/10.1158/2159-8290.CD-14-0337

Douillard, J. Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., *et al.* (2013). Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. The New England Journal of Medicine, 369(11), 1023-1034. https://doi.org/10.1056/NEJMoa1305275

Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., *et al.* (2007). MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science, 316(5827), 1039-1043. https://doi.org/10.1126/science.1141478

Fassunke J, Müller F, Petzold A, Dietlein F, Wermke M, *et al.* (2023). Targeting triple-mutant EGFR with JBJ-04-125-02. J Thorac Oncol. 18(2), 267-276.

Finlay, M. R. V., Anderton, M., Ashton, S., Ballard, P., Bethel, P. A., Box, M. R., *et al.* (2014). Discovery of osimertinib (AZD9291): An irreversible EGFR mutant-selective inhibitor for T790M resistance in non-small-cell lung cancer. Journal of Medicinal Chemistry, 57(20), 8249-8267. https://doi.org/10.1021/jm501191y

Garrison, B., Genova, C., Mazieres, J., Tan, D. S. W., Camidge, D. R., Leighl, N., &#gethillips; & Goto, K. (2023). Trastuzumab deruxtecan in HER2-overexpressing EGFR-mutant NSCLC: Early results from DESTINY-Lung trials. Journal of Thoracic Oncology, 18(4), 468-478. https://doi.org/10.1016/j.jtho.2022.12.009

GlobalData. (2024). EGFR inhibitors market size and forecast to 2032. Retrieved from https://www.globaldata.com

Goto, Y., Hida, T., Toyozawa, R., Seto, T., Takahashi, T., Nokihara, H., *et al.* (2023). Safety and activity of datopotamab deruxtecan in NSCLC: A phase I study. Journal of Clinical Oncology, 41(15_suppl), 8510.

J&J Pharmaceuticals. (2023). Amivantamab receives FDA approval for EGFR exon 20 insertions [Press release]. Retrieved from https://www.janssen.com

Jänne, P. A., Yang, J. C., Kim, D. W., Planchard, D., Ohe, Y., Ramalingam, S. S., *et al.* (2015). AZD9291 in EGFR T790M-positive lung cancer. New England Journal of Medicine, 372(18), 1689-1699. https://doi.org/10.1056/NEJMoa1411817

Jia, Y., Yun, C. H., Park, E., Ercan, D., Manuia, M., Juarez, J., *et al.* (2016). Overcoming EGFR T790M and C797S resistance with mutant-selective allosteric inhibitors. Nature, 534(7605), 129-132. https://doi.org/10.1038/nature17960

Robichaux JP, Le X, Vijayan RSK, Hicks JK, Heeke S, Elamin YY, *et al.* (2021). Structure-based classification predicts drug response in EGFR-mutant NSCLC. Nature. 597(7878), 732-737.

Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., *et al.* (2005). EGFR mutation and resistance to gefitinib. The New England Journal of Medicine, 352(8), 786-792. https://doi.org/10.1056/NEJMoa044238

Le X, *et al.* (2023). BLU-945 in osimertinib-resistant NSCLC: Phase I data. J Clin Oncol. 41(15_suppl), 9007.

Le, X., Ponce, S., Cappuzzo, F., Cho, B. C., Nicolson, M., Garassino, M. C., *et al.* (2023). The evolving landscape of EGFR inhibitor resistance in lung cancer. Nature Reviews Clinical Oncology, 20(1), 21-37. https://doi.org/10.1038/s41571-022-00661-4

Li, B. T., Shen, R., Buonocore, D. J., Olah, Z. T., Ni, A., Ginsberg, M. S., &#gethillips; & Riely, G. J. (2018). HER2 amplification and response to afatinib in EGFR-mutant NSCLC with acquired resistance to EGFR inhibitors. Clinical Cancer Research, 24(10), 2715-2725. https://doi.org/10.1158/1078-0432.CCR-17-3335

Li, D., Ambrogio, L., Shimamura, T., Kubo, S., Takahashi, M., Chirieac, L. R., *et al.* (2008). BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene, 27(34), 4702-4711. https://doi.org/10.1038/onc.2008.109

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., *et al.* (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of NSCLC to gefitinib. The New England Journal of Medicine, 350(21), 2129-2139. https://doi.org/10.1056/NEJMoa040938

Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., *et al.* (2010). Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. The New England Journal of Medicine, 362(25), 2380-2388. https://doi.org/10.1056/NEJMoa0909530

Marcoux, N., Gettinger, S. N., O'Kane, G., Arbour, K. C., Neal, J. W., Husain, H., &#gethillips; & Yu, H. A. (2019). EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and respond to platinum chemotherapy. Journal of Clinical Oncology, 37(30), 2783-2790. https://doi.org/10.1200/JCO.19.00230

Melosky, B., Hirsh, V., Morzycki, W., Bajcar, J., Rodrigues, L., & Laskin, J. (2015). Management of skin rash during EGFR-targeted therapy. Current Oncology, 22(2), 123-132. https://doi.org/10.3747/co.22.2206

Midha, A., Dearden, S., & McCormack, R. (2015). EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: A systematic review and global map by ethnicity. American Journal of Cancer Research, 5(9), 2892-2911.

Mok, T. S., Cheng, Y., Zhou, X., Lee, K. H., Nakagawa, K., Niho, S., *et al.* (2017). Dacomitinib versus gefitinib in patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): A randomised, open-label, phase 3 trial. The Lancet Oncology, 18(11), 1454-1466. https://doi.org/10.1016/S1470-2045(17)30608-3

Mok, T. S., Wu, Y. L., Ahn, M. J., Garassino, M. C., Kim, H. R., Ramalingam, S. S., *et al.* (2017). Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. New England Journal of Medicine, 376(7), 629-640. https://doi.org/10.1056/NEJMoa1612674

Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D. T., Saijo, N., *et al.* (2009). Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. The New England Journal of Medicine, 361(10), 947-957. https://doi.org/10.1056/NEJMoa0810699

Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D. T., Saijo, N., *et al.* (2009). Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. The New England Journal of Medicine, 361(10), 947-957. https://doi.org/10.1056/NEJMoa0810699

Normanno, N., De Luca, A., Bianco, C., Strizzi, L., Mancino, M., Maiello, M. R., *et al.* (2006). Epidermal growth factor receptor (EGFR) signaling in cancer. Gene, 366(1), 2-16. https://doi.org/10.1016/j.gene.2005.10.018

Offin, M., Chan, J. M., Tenet, M., Rizvi, H., Shen, R., Riely, G. J., &#gethillips; & Yu, H. A. (2019). Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant NSCLC at risk for histologic transformation and inferior clinical outcomes. Journal of Thoracic Oncology, 14(10), 1784-1793. https://doi.org/10.1016/j.jtho.2019.06.010

Piotrowska, Z., Isozaki, H., Lennerz, J. K., Gainor, J. F., Lennes, I. T., Zhu, V. W., *et al.* (2018). Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical outcomes. Journal of Clinical Oncology, 36(15_suppl), 9020. https://doi.org/10.1200/JCO.2018.36.15_suppl.9020

Piotrowska, Z., Neal, J. W., Camidge, D. R., Gadgeel, S. M., Sequist, L. V., & Wirth, L. J., *et al.* (2023). BLU-945 in EGFR-mutant NSCLC: Preliminary safety and efficacy from phase I trial. Journal of Clinical Oncology, 41(15_suppl), 9007. https://doi.org/10.1200/JCO.2023.41.15_suppl.9007

Planchard, D., & Besse, B. (2019). Treatment of EGFR-mutated NSCLC: Recent advances and future perspectives. Targeted Oncology, 14(3), 289-299. https://doi.org/10.1007/s11523-019-00632-7

Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong KK, *et al.* (2008). The T790M mutation in EGFR kinase causes resistance by increasing affinity for ATP. Proc Natl Acad Sci U S A. 105(6), 2070-2075.

ResearchAndMarkets. (2024). EGFR inhibitors global market analysis, trends, and forecast. Retrieved from https://www.researchandmarkets.com

Reungwetwattana, T., Nakagawa, K., Cho, B. C., Cobo, M., Cho, E. K., Bertolini, A., *et al.* (2018). CNS response to osimertinib in patients with T790M-positive NSCLC: Pooled data from AURA trials. Journal of Clinical Oncology, 36(26), 2702-2709. https://doi.org/10.1200/JCO.2018.78.3118

Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., *et al.* (2012). Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive NSCLC (EURTAC): A multicentre, open-label, randomized phase 3 trial. The Lancet Oncology, 13(3), 239-246. https://doi.org/10.1016/S1470-2045(11)70393-X

Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., *et al.* (2009). Screening for EGFR mutations in lung cancer. The New England Journal of Medicine, 361(10), 958-967. https://doi.org/10.1056/NEJMoa0904554

Schoenfeld, A. J., & Yu, H. A. (2020). The evolving landscape of resistance to osimertinib. Journal of Thoracic Oncology, 15(1), 18-21. https://doi.org/10.1016/j.jtho.2019.11.007

Schoenfeld, A. J., Chan, J. M., Kubota, D., Sima, C. S., Ladanyi, M., Rizvi, H., &#gethillips; & Arcila, M. E. (2020). Tumor heterogeneity and evolution after acquired resistance to EGFR-TKIs in patients with EGFR-mutant lung cancers. Journal of Clinical Investigation, 130(10), 5692-5705. https://doi.org/10.1172/JCI138744

Sequist LV, *et al.* Osimertinib + savolitinib in MET-amplified EGFR-mutant NSCLC. Lancet Oncol. 2020; 21(3): 373-86.

Sequist, L. V., Han, J. Y., Ahn, M. J., Cho, B. C., Yu, H., Kim, S. W., *et al.* (2020). Osimertinib plus savolitinib in patients with EGFR-mutant NSCLC and MET amplification after EGFR TKI resistance. Lancet Oncology, 21(3), 373-386. https://doi.org/10.1016/S1470-2045(19)30785-5

Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., *et al.* (2011). Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Science Translational Medicine, 3(75), 75ra26. https://doi.org/10.1126/scitranslmed.3002003

Sequist, L. V., Yang, J. C., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., *et al.* (2013). Phase III study of afatinib versus cisplatin/pemetrexed in patients with EGFR-mutated lung adenocarcinoma (LUX-Lung 3). Journal of Clinical Oncology, 31(27), 3327-3334. https://doi.org/10.1200/JCO.2012.44.2806

Seshacharyulu, P., Ponnusamy, M. P., Haridas, D., Jain, M., Ganti, A. K., & Batra, S. K. (2012). Targeting the EGFR signaling pathway in cancer therapy. Expert Opinion on Therapeutic Targets, 16(1), 15-31. https://doi.org/10.1517/14728222.2011.643754

Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007). Epidermal growth factor receptor mutations in lung cancer. Nature Reviews Cancer, 7(3), 169-181. https://doi.org/10.1038/nrc2088

Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., *et al.* (2005). Erlotinib in previously treated non-small-cell lung cancer. The New England Journal of Medicine, 353(2), 123-132. https://doi.org/10.1056/NEJMoa050753

Smaill, J. B., Rewcastle, G. W., Loo, J. A., Greis, K. D., Chan, O. H., Reyner, E. L., *et al.* (2016). Tyrosine kinase inhibitors targeting EGFR: Strategies to overcome resistance. Medicinal Research Reviews, 36(3), 440-475. https://doi.org/10.1002/med.21387

Solca, F., Dahl, G., Zoephel, A., Bader, G., Sanderson, M., Klein, C., *et al.* (2012). Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. Journal of Pharmacology and Experimental Therapeutics, 343(2), 342-350. https://doi.org/10.1124/jpet.112.197756

Song Y, *et al.* (2023). Structure-based design of novel inhibitors targeting EGFR C797S mutants. Bioorg Med Chem Lett. 63, 129737.

Song, K. A., Niederst, M. J., Lochmann, T. L., & Hata, A. N. (2020). Acquired resistance to osimertinib in EGFR-mutant NSCLC: Mechanisms and emerging therapeutic strategies. Cancer Research, 80(4), 701-712. https://doi.org/10.1158/0008-5472.CAN-19-1002

Soria, J. C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., *et al.* (2018). Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. The New England Journal of Medicine, 378(2), 113-125. https://doi.org/10.1056/NEJMoa1713137

Thress, K. S., Paweletz, C. P., Felip, E., Cho, B. C., Stetson, D., Dougherty, B., *et al.* (2015). Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nature Medicine, 21(6), 560-562. https://doi.org/10.1038/nm.3854

Wang S, Song Y, Liu D. EAI045: the first allosteric inhibitor overcomes EGFR T790M and C797S resistance. Signal Transduct Target Ther. 2016; 1(1): 16018.

To, C., Beyett, T. S., Jang, J., Feng, W. W., Bahcall, M., Haikala, H. M., *et al.* (2022). An allosteric inhibitor against the EGFR resistance mutation C797S. Cancer Discovery, 12(3), 372-383. https://doi.org/10.1158/2159-8290.CD-21-1188

Walter, A. O., Sjin, R. T., Haringsma, H. J., Ohashi, K., Sun, J., Lee, K., *et al.* (2013). Discovery of a mutant-selective EGFR inhibitor. Cancer Discovery, 3(12), 1404-1415. https://doi.org/10.1158/2159-8290.CD-13-0314

Wu, Y. L., Zhou, C., Hu, C. P., Feng, J., Lu, S., Huang, Y., *et al.* (2014). Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harboring EGFR mutations (LUX-Lung 6): An open-label, randomised phase 3 trial. The Lancet Oncology, 15(2), 213-222. https://doi.org/10.1016/S1470-2045(13)70604-1

Yarden, Y., & Sliwkowski, M. X. (2001). Untangling the ErbB signalling network. Nature Reviews Molecular Cell Biology, 2(2), 127-137. https://doi.org/10.1038/35052073

Yu, H. A., Arcila, M. E., Rekhtman, N., Sima, C. S., Zakowski, M. F., Pao, W., *et al.* (2013). Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clinical Cancer Research, 19(8), 2240-2247. https://doi.org/10.1158/1078-0432.CCR-12-2246

Yu, H. A., Sima, C. S., Shen, R., Kass, S., Gainor, J., Krug, L. M., &#gethillips; & Riely, G. J. (2020). Analysis of resistance mechanisms to osimertinib in EGFR-mutant NSCLC using tissue and cfDNA. Journal of Thoracic Oncology, 15(9), 1430-1441. https://doi.org/10.1016/j.jtho.2020.04.014

Yun, C. H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K. K., *et al.* (2008). The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proceedings of the National Academy of Sciences of the United States of America, 105(6), 2070-2075. https://doi.org/10.1073/pnas.0709662105

Zhang Y, Jiang T, Zhao Y, *et al.* (2022). Machine learning model predicts EGFR-TKI resistance using plasma ctDNA. J Thorac Oncol. 17(5), 697-707.

Zhou, C., Wu, Y. L., Chen, G., Feng, J., Liu, X. Q., Wang, C., *et al.* (2011). Erlotinib versus chemotherapy in advanced NSCLC patients with EGFR mutations: A Chinese cohort study. Lancet Oncology, 12(8), 735-742. https://doi.org/10.1016/S1470-2045(11)70184-X

Suda, K., Tomizawa, K., Osada, H., Maehara, Y., Yatabe, Y., & Mitsudomi, T. (2017). Conversion from EGFR T790M to C797S mutation as a mechanism of acquired resistance to osimertinib. Journal of Thoracic Oncology, 12(1), 152-157. https://doi.org/10.1016/j.jtho.2016.08.147

U.S. Food and Drug Administration (FDA). (n.d.). Drugs@FDA: FDA-approved drugproducts. Retrieved July 23, 2025, from https://www.accessdata.fda.gov/scripts/cder/daf/

Walter, A. O., Sjin, R. T., Haringsma, H. J., Ohashi, K., Sun, J., Lee, K., *et al*. (2013). Discovery of a mutant-selective EGFR inhibitor. Cancer Discovery, 3(12), 1404–1415. https://doi.org/10.1158/2159-8290.CD-13-0314

Wu, Y. L., Zhou, C., Hu, C. P., Feng, J., Lu, S., Huang, Y., *et al.* (2014). Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harboring EGFR mutations (LUX-Lung 6): An open-label, randomised phase 3 trial. The Lancet Oncology, 15(2), 213–222. https://doi.org/10.1016/S1470-2045(13)70604-1

Yarden, Y., & Sliwkowski, M. X. (2001). Untangling the ErbB signalling network. Nature Reviews Molecular Cell Biology, 2(2), 127–137. https://doi.org/10.1038/35052073

Yu, H. A., Arcila, M. E., Rekhtman, N., Sima, C. S., Zakowski, M. F., Pao, W., *et al*. (2013). Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clinical Cancer Research, 19(8), 2240–2247. https://doi.org/10.1158/1078-0432.CCR-12-2246

Yu, H. A., Sima, C. S., Shen, R., Kass, S., Gainor, J., Krug, L. M., ... & Riely, G. J. (2020). Analysis of resistance mechanisms to osimertinib in EGFR-mutant NSCLC using tissue and cfDNA. Journal of Thoracic Oncology, 15(9), 1430–1441. https://doi.org/10.1016/j.jtho.2020.04.014

Yun, C. H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K. K., *et al*. (2008). The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proceedings of the National Academy of Sciences of the United States of America, 105(6), 2070–2075. https://doi.org/10.1073/pnas.0709662105

Zhang Y, Jiang T, Zhao Y, et al. Machine learning model predicts EGFR-TKI resistance using plasma ctDNA. J Thorac Oncol. 2022;17(5):697–707.

Zhou, C.,Wu, Y. L., Chen, G., Feng, J., Liu, X. Q., Wang, C., *et al*. (2011). Erlotinib versus chemotherapy in advanced NSCLC patients with EGFR mutations: A Chinese cohort study. Lancet Oncology, 12(8), 735–742. https://doi.org/10.1016/S1470-2045(11)70184-X

Cite this article: Magar VK, Khavane KB. EGFR Inhibitors: Current Status, Resistance Mechanisms, and Market Insight. Indian J Pharmacy Practice. 2026;19(2):139-50.